Precision oncology requires an understanding of the genes and pathways that dictate therapeutic response. Through specialized analysis of drug sensitivity patterns across hundreds of genomically annotated cancer cell lines, specific and actionable drivers of intrinsic resistance have been identified.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Francies, H. E. et al. Nat. Cancer 1, 482–492 (2020).
Chang, L. et al. Cancer Cell 39, 466–479 (2021).
Rees, M. G. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-022-00980-1 (2022).
Konieczkowski, D. J. et al. Cancer Cell 33, 801–815 (2018).
Iorio, F. et al. Cell 166, 740–754 (2016).
Seashore-Ludlow, B. et al. Cancer Discov. 5, 1210–1223 (2015).
Barretina, J. et al. Nature 483, 603–607 (2012).
Wood, K. C. Cancer Res. 75, 4247–4251 (2015).
Griner, L. A. M. et al. Proc. Natl. Acad. Sci. USA 111, 2349–2354 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interest.
Rights and permissions
About this article
Cite this article
Wood, K.C. Drivers of intrinsic resistance. Nat Chem Biol 18, 579–581 (2022). https://doi.org/10.1038/s41589-022-00980-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-022-00980-1
This article is cited by
-
Drivers of intrinsic resistance
Nature Chemical Biology (2022)
